TN2015000100A1 - Pde9i with imidazo pyrazinone backbone - Google Patents
Pde9i with imidazo pyrazinone backboneInfo
- Publication number
- TN2015000100A1 TN2015000100A1 TNP2015000100A TN2015000100A TN2015000100A1 TN 2015000100 A1 TN2015000100 A1 TN 2015000100A1 TN P2015000100 A TNP2015000100 A TN P2015000100A TN 2015000100 A TN2015000100 A TN 2015000100A TN 2015000100 A1 TN2015000100 A1 TN 2015000100A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compound
- formula
- effective amount
- therapeutically effective
- pde9i
- Prior art date
Links
- MPWOBEOETVOESI-UHFFFAOYSA-N imidazo[4,5-b]pyrazin-2-one Chemical group N1=CC=NC2=NC(=O)N=C21 MPWOBEOETVOESI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011001692 | 2011-10-10 | ||
| PCT/EP2012/069936 WO2013053690A1 (fr) | 2011-10-10 | 2012-10-09 | Pde9i ayant un squelette imidazo pyrazinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2015000100A1 true TN2015000100A1 (en) | 2016-06-29 |
Family
ID=47019007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2015000100A TN2015000100A1 (en) | 2011-10-10 | 2015-03-16 | Pde9i with imidazo pyrazinone backbone |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9643970B2 (fr) |
| EP (2) | EP3121178B1 (fr) |
| JP (1) | JP2015531401A (fr) |
| CN (2) | CN106905324B (fr) |
| AU (2) | AU2012323085B2 (fr) |
| BR (1) | BR112015007731B1 (fr) |
| CA (1) | CA2886885C (fr) |
| HK (1) | HK1211023A1 (fr) |
| IL (2) | IL237836A (fr) |
| IN (1) | IN2015DN02829A (fr) |
| MA (1) | MA37958B1 (fr) |
| MX (2) | MX381326B (fr) |
| SG (1) | SG11201502728WA (fr) |
| TN (1) | TN2015000100A1 (fr) |
| WO (1) | WO2013053690A1 (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3121178B1 (fr) * | 2011-10-10 | 2018-09-19 | H. Lundbeck A/S | 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one en tant qu'inhibiteur de pde9 |
| EP3392244A1 (fr) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines en tant qu'inhibiteurs de lsd1 |
| WO2015123437A1 (fr) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines en tant qu'inhibiteurs de lsd1 |
| SMT201900620T1 (it) | 2014-02-13 | 2020-01-14 | Incyte Corp | Ciclopropilammine come inibitori di lsd1 |
| PL3105218T3 (pl) | 2014-02-13 | 2020-03-31 | Incyte Corporation | Cyklopropyloaminy jako inhibitory lsd1 |
| WO2016007731A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1 |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| ES2757948T3 (es) | 2015-04-03 | 2020-04-30 | Incyte Corp | Compuestos heterocíclicos como inhibidores LSD1 |
| JO3627B1 (ar) * | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| SI3865484T1 (sl) * | 2015-07-07 | 2024-05-31 | H. Lundbeck A/S | Zaviralec pde9 z imidazo pirazinonsko hrbtenico za zdravljenje perifernih bolezni |
| TW201717948A (zh) * | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| AU2016306555B2 (en) | 2015-08-12 | 2021-01-28 | Incyte Holdings Corporation | Salts of an LSD1 inhibitor |
| MX376639B (es) * | 2015-11-09 | 2025-03-07 | Astrazeneca Ab | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer. |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| IL262488B (en) | 2016-04-22 | 2022-08-01 | Incyte Corp | lsdi inhibitor formulations |
| MX2018016127A (es) * | 2016-07-06 | 2019-05-30 | Imara Inc | Inhibidores de pde9 para el tratamiento de enfermedades perifericas. |
| US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| CA3041595A1 (fr) * | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Traitements combines comprenant l'administration d'imidazopyrazinones |
| CA3045745A1 (fr) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Derives de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitues par de la piperidine, de la morpholine ou de la piperazine utilises en tant qu'inhibiteurs d'oga |
| RS65143B1 (sr) * | 2017-05-26 | 2024-02-29 | Cardurion Pharmaceuticals Inc | Postupci izrade i upotrebe pde9 inhibitora |
| KR20200013758A (ko) | 2017-06-08 | 2020-02-07 | 머크 샤프 앤드 돔 코포레이션 | 피라졸로피리미딘 pde9 억제제 |
| WO2019101511A1 (fr) | 2017-11-23 | 2019-05-31 | Basf Se | Trifluorométhyloxadiazoles substitués permettant de lutter contre des champignons phytopathogènes |
| KR20210014662A (ko) | 2018-05-25 | 2021-02-09 | 이마라 인크. | 6-[(3S,4S)-4-메틸-1-(피리미딘-2-일메틸)피롤리딘-3-일]-3-테트라히드로피란-4-일-7H-이미다조[1,5-a]피라진-8-온의 일수화물 및 결정형 |
| JP2021527662A (ja) * | 2018-06-20 | 2021-10-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｏｇａ阻害化合物 |
| CN112996512B (zh) | 2018-08-31 | 2025-01-03 | 卡都瑞恩医药公司 | 用于治疗镰状细胞病的pde9抑制剂 |
| WO2020047198A1 (fr) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Sels d'un inhibiteur de lsd1 et leurs procédés de préparation |
| WO2020206336A1 (fr) * | 2019-04-05 | 2020-10-08 | Imara Inc. | Inhibiteurs de pde9 pour le traitement de la drépanocytose |
| CN114072151A (zh) * | 2019-05-07 | 2022-02-18 | 伊马拉公司 | 用于治疗地中海贫血的pde9抑制剂 |
| WO2022036111A1 (fr) * | 2020-08-13 | 2022-02-17 | Imara Inc. | Méthodes et compositions pour le traitement de la maladie à hématies falciformes |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135462A0 (en) | 1997-11-12 | 2001-05-20 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| BR0007613A (pt) | 1999-01-20 | 2001-10-30 | Dresden Arzneimittel | Aplicação de imidazo[1,5-a]-pirido[3,2-e]-pirazinonascomo medicamento |
| IL161155A0 (en) | 2001-11-02 | 2004-08-31 | Pfizer Prod Inc | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| GB2388111A (en) | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| WO2005041972A1 (fr) | 2003-10-31 | 2005-05-12 | Pfizer Products Inc. | Inhibition de la phosphodiesterase 9 comme traitement d'etats associes a l'obesite |
| CA2620223A1 (fr) | 2005-09-02 | 2007-03-08 | Abbott Laboratories | Nouveaux heterocycles a base imidazo |
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| WO2008029589A1 (fr) | 2006-09-08 | 2008-03-13 | Tokuyama Corporation | Procédé et matériel servant à produire un nitrure d'un élément du groupe iii |
| KR20090097918A (ko) * | 2006-12-13 | 2009-09-16 | 아스카 세이야쿠 가부시키가이샤 | 요로계 질환의 처치제 |
| ES2536906T3 (es) | 2006-12-13 | 2015-05-29 | Aska Pharmaceutical Co., Ltd. | Derivado de quinoxalina |
| UA94660C2 (en) * | 2007-05-11 | 2011-05-25 | Пфайзер Инк. | Amino-heterocyclic compounds |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| WO2011028820A1 (fr) | 2009-09-02 | 2011-03-10 | Concert Pharmaceuticals, Inc. | Dérivés substitués de composés [4.3.0] hétéroaryle bicycliques |
| ES2610360T3 (es) * | 2010-09-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Compuestos de imidazotriazinona |
| KR101943680B1 (ko) | 2011-10-07 | 2019-01-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체 |
| EP3121178B1 (fr) * | 2011-10-10 | 2018-09-19 | H. Lundbeck A/S | 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one en tant qu'inhibiteur de pde9 |
| US9434733B2 (en) | 2012-01-26 | 2016-09-06 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone |
| WO2013142269A1 (fr) | 2012-03-19 | 2013-09-26 | Envivo Pharmaceuticals, Inc. | Composés d'imidazotriazinone |
-
2012
- 2012-10-09 EP EP16185105.0A patent/EP3121178B1/fr active Active
- 2012-10-09 AU AU2012323085A patent/AU2012323085B2/en active Active
- 2012-10-09 WO PCT/EP2012/069936 patent/WO2013053690A1/fr active Application Filing
- 2012-10-09 SG SG11201502728WA patent/SG11201502728WA/en unknown
- 2012-10-09 BR BR112015007731-5A patent/BR112015007731B1/pt active IP Right Grant
- 2012-10-09 MA MA37958A patent/MA37958B1/fr unknown
- 2012-10-09 MX MX2019014982A patent/MX381326B/es unknown
- 2012-10-09 IN IN2829DEN2015 patent/IN2015DN02829A/en unknown
- 2012-10-09 CA CA2886885A patent/CA2886885C/fr active Active
- 2012-10-09 CN CN201710247417.1A patent/CN106905324B/zh active Active
- 2012-10-09 US US14/434,308 patent/US9643970B2/en active Active
- 2012-10-09 CN CN201280076285.6A patent/CN104703987B/zh active Active
- 2012-10-09 MX MX2015004422A patent/MX370433B/es active IP Right Grant
- 2012-10-09 EP EP12772769.1A patent/EP2906562B1/fr active Active
- 2012-10-09 JP JP2015535994A patent/JP2015531401A/ja active Pending
-
2015
- 2015-03-16 TN TNP2015000100A patent/TN2015000100A1/fr unknown
- 2015-03-19 IL IL237836A patent/IL237836A/en active IP Right Grant
- 2015-11-27 HK HK15111740.3A patent/HK1211023A1/xx unknown
-
2017
- 2017-03-08 US US15/452,827 patent/US9993477B2/en active Active
- 2017-03-20 AU AU2017201873A patent/AU2017201873C1/en active Active
- 2017-07-12 IL IL253448A patent/IL253448A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000100A1 (en) | Pde9i with imidazo pyrazinone backbone | |
| PH12014501695B1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
| MY152949A (en) | Novel phenylimidazole derivatives as pde10a enzyme inhibitors | |
| TN2012000287A1 (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
| PH12013500968A1 (en) | Imidazole derivatives as pde10a enzyme inhibitors | |
| UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a | |
| TN2012000271A1 (en) | Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors | |
| PH12012501202A1 (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
| TN2014000288A1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
| MX336915B (es) | Derivados de imidazol como inhibidores de la enzima pde10a. | |
| TN2013000200A1 (en) | Imidazole derivatives as pde 10a enzyme inhibitors | |
| CY1116689T1 (el) | Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a |